PTC Therapeutics elevates biotech buyout CEO to chief development officer

Pancreatic Cancer Ribbon
Cancer ribbons (Photo by ThitareeSarmkasat/iStock/Getty Images Plus)

Late last year, PTC Therapeutics bought up California-based BioElectron Technology in a small deal, nabbing its leading drug, EPI-743, for metabolic and mitochondrial disorders.

Now, it’s also adding the company’s former CEO and chief scientific officer to its top clinical team, as Matthew Klein, M.D., becomes its chief development officer. In this role, Klein “will be responsible for the development of our clinical stage programs,” the biotech said.

This includes its early pipeline work around gene therapy, nonsense mutation, splicing and oncology, according to its site, with targets including Huntingdon’s disease, Angelman syndrome, relapsed/refractory acute leukemias, ovarian cancer and others.

Sponsored by BHE

[Webinar] State of Data Analytics and Machine Learning in the Life Sciences Industry: 2020 Benchmarking Survey

Thursday, June 25, 2020 | 2:00pm ET | 11:00am PT

Join us Thursday, June 25th for a look at the current state of analytics in the life sciences industry. We will present the results from our industry survey with FiercePharma on how 100 of your peers are leveraging data analytics to respond to today’s challenges and generate timely, high value insights.

PTC markets Emflaza, a controversial Duchenne muscular dystrophy (DMD) treatment, in the U.S. It sells another DMD drug, Translarna, in Europe, and Tegsedi, which treats polyneuropathy of hereditary transthyretin-mediated amyloidosis, in Latin America.

SPECIAL REPORT: The top 20 pharma companies by 2019 revenue

It also has a 2020 date with the FDA for a potential approval for its Roche-partnered spinal muscular atrophy therapy risdiplam, which will compete with the likes of Biogen and Novartis but could still be a solid blockbuster at peak.

Klein joined PTC last year, initially as global head of gene and mitochondrial therapies, after the BioElectron deal.

Suggested Articles

Researchers at the University of Maryland are developing an experimental diagnostic for COVID-19 that could provide a visual result in 10 minutes.

The FDA approved its first radioactive diagnostic dye designed to map out the characteristic tau protein tangles found in brains with Alzheimer's.

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.